Reviewing ImageneBio (NASDAQ:IMA) & Bicara Therapeutics (NASDAQ:BCAX)

ImageneBio (NASDAQ:IMA) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Volatility & Risk

ImageneBio has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Bicara Therapeutics has a beta of -0.81, suggesting that its stock price is 181% less volatile than the S&P 500.

Profitability

This table compares ImageneBio and Bicara Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Insider & Institutional Ownership

75.0% of ImageneBio shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ImageneBio and Bicara Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800,000.00	80.81	-$45.35 million	($5.79)	-1.05
Bicara Therapeutics	N/A	N/A	-$137.95 million	($2.78)	-10.94

ImageneBio has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for ImageneBio and Bicara Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2	1	0	1	2.00
Bicara Therapeutics	1	3	10	1	2.73

ImageneBio presently has a consensus target price of $26.50, suggesting a potential upside of 336.57%. Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential downside of 0.42%. Given ImageneBio’s higher possible upside, research analysts clearly believe ImageneBio is more favorable than Bicara Therapeutics.

About ImageneBio

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

About Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.